Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BETP
Cat. No.:
OB0225LY-0266
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
BETP is a selective inhibitor of BET (bromodomain and extraterminal) capable of influencing epigenetic regulatory processes.
Synonym:
1371569-69-5; (4-(3-Benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; 2-Ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine; 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine
CAS No.:
1371569-69-5
Compound CID:
49868481
Formula:
C20H17F3N2O2S
Formula Weight:
406.42
Specification
Relative Density:
1.39 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BETP can be used to study the mechanisms of gene expression regulation.
Library Information
Targets:
Glucagon receptor
Receptors:
GLP-1
Pathways:
GPCR/G protein
Plate Number:
AOCL-4
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
25 mg/mL; 61.51 mM
Solubility:
Insoluble in water.
